finanzen.net
14.01.2019 13:30
Bewerten
(0)

Global Xerostomia Therapeutics Market Research Report 2019-2023

DRUCKEN

DUBLIN, Jan. 14, 2019 /PRNewswire/ --

The "Global Xerostomia Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The xerostomia therapeutics market to grow at a CAGR of over 3% during the forecast period.

The most common disease that causes xerostomia is an inflammatory autoimmune disease. Additionally, central nervous system-related diseases including stress, depression, and anxiety can also lead to xerostomia.

Moreover, trauma to the head and neck area can alter the nerve stimuli to the mouth and impair the function to the salivary glands. Therefore, the rising incidence of the health conditions or diseases that are high-risk factors for xerostomia is expected to continue to support the growth of the global xerostomia therapeutics market during the forecast period.

Market Overview

Growing geriatric population

The increasing number of people with xerostomia is directly related to the growing geriatric population. The number of old people worldwide has been growing significantly over the years. This expected to contribute significantly to the market as this high growth in the older population helps to drive the sales of various therapeutics markets during our forecast period.

Product recalls and tedious drug approval process

Regulatory bodies have framed stringent regulations to grant marketing approval for therapeutics that are being newly developed for the treatment of xerostomia. Many applications rejected either due to the inadequate performance of the drug or because the information on the drug, which is submitted is unsatisfactory. Such stringent government regulations can lead to a delay in drug in drug approval which in turn hampers the growth of the market.

Competitive Landscape

The xerostomia therapeutics market is fragmented due to presence of many vendors in the market. The pharmaceutical companies are forming strategic collaborations which will enhance the R&D activities for new drugs for the management xerostomia.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Comparison by product
  • OTC
  • Prescription
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

PART 10: VENDOR LANDSCAPE

PART 11: TRENDS

PART 12: VENDOR LANDSCAPE

  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Colgate-Palmolive
  • Daiichi Sankyo
  • Eisai
  • GlaxoSmithKline
  • Orahealth

For more information about this report visit https://www.researchandmarkets.com/research/x48hzf/global_xerostomia?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/global-xerostomia-therapeutics-market-research-report-2019-2023-300777497.html

SOURCE Research and Markets

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX schließt im Plus -- US-Handel endet grün -- Morgan Stanley setzt Tesla unter Druck -- Ceconomy: Umbaukosten belasten -- Daimler will bei Verwaltung sparen -- EVOTEC, LEONI, Siemens im Fokus

Pfund gewinnt stark nach Spekulationen über zweites Referendum. thyssenkrupp-Aufsichtsrat genehmigt Neuausrichtung einstimmig. Restaurantkette von Starkoch Jamie Oliver ist insolvent. adidas-Aktie geht nach kurzer Pause wieder auf Rekordjagd. OECD senkt globale Wachstumsprognose.

Die 5 beliebtesten Top-Rankings

Diese Aktien hat Warren Buffett im Depot
Die Änderungen unter den Top-Positionen
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
In diesen Berufen bekommt man das höchste Gehalt
Mit welchem Beruf kommt man am ehesten an die Spitze?
Städte für Millionäre
Hier fühlen sich die Vermögenden am wohlsten
In diesen Ländern ist Netflix am billigsten
Wo zahlen Abonnenten am wenigsten?
mehr Top Rankings

Umfrage

Die rechtspopulistische FPÖ in Österreich hat für einen Skandal gesorgt. Wie glauben Sie wird sich das auf die Europawahlen auswirken?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Huawei TechnologiesHWEI11
Daimler AG710000
Deutsche Bank AG514000
TeslaA1CX3T
CommerzbankCBK100
Amazon906866
BayerBAY001
BASFBASF11
NEL ASAA0B733
Apple Inc.865985
Deutsche Telekom AG555750
Infineon AG623100
EVOTEC SE566480
Allianz840400